{'fraction_non_alphanumeric': 0.022727272727272728, 'fraction_numerical': 0.0, 'mean_word_length': 5.451219512195122, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients

Despite advances in chemo-immunotherapy of chronic lymphocytic leukemia, a choice of therapy is a frequent challenge in patients with a refractory form of the disease, autoimmune hemolytic complications, and also in high-risk patients with cytogenetic changes. The use of ibrutinib, one of Bruton’s tyrosine kinase inhibitors, allows to overcome the resistance to anticancer therapy without adverse eff ects on patients’ quality of life.